|
1
|
Fatima S, Ahmad SI and Ahmad HR: The
intercept and slope of breathlessness/chest pain-heart rate
relationship in patients with coronary artery disease using
exercise tolerance test. J Pak Med Assoc. 62:382–385.
2012.PubMed/NCBI
|
|
2
|
Kang YH, Lao HY, Yu XY, Chen JY and Zhong
SL: Progress in genetic and epigenetic research on in-stent
restenosis after percutaneous coronary interventions. Zhonghua Yi
Xue Yi Chuan Xue Za Zhi. 29:38–42. 2012.(In Chinese).
|
|
3
|
Ge J, Han Y, Jiang H, et al; RACTS
(Randomized Prospective Antiplatelet Trial of Cilostazol Versus
Ticlopidine in Patients Undergoing Coronary Stenting) Trial
Investigators. RACTS: a prospective randomized antiplatelet trial
of cilostazol versus ticlopidine in patients undergoing coronary
stenting: long-term clinical and angiographic outcome. J Cardiovasc
Pharmacol. 46:162–166. 2005. View Article : Google Scholar
|
|
4
|
Han Y, Wang S, Li Y, et al: Cilostazol
improves long-term outcomes after coronary stent implantation. Am
Heart J. 150:5682005.PubMed/NCBI
|
|
5
|
Nagaoka N, Matsubara T, Okazaki K, Masuda
N, Shikaura K and Hotta A: Comparison of ticlopidine and cilostazol
for the prevention of restenosis after percutaneous transluminal
coronary angioplasty. Jpn Heart J. 42:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hashiguchi M, Ohno K, Nakazawa R, Kishino
S, Mochizuki M and Shiga T: Comparison of cilostazol and
ticlopidine for one-month effectiveness and safety after elective
coronary stenting. Cardiovasc Drugs Ther. 18:211–217. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harding SA, Walters DL, Palacios IF and
Oesterle SN: Adjunctive pharmacotherapy for coronary stenting. Curr
Opin Cardiol. 16:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanabe Y, Ito E, Nakagawa I and Suzuki K:
Effect of cilostazol on restenosis after coronary angioplasty and
stenting in comparison to conventional coronary artery stenting
with ticlopidine. Int J Cardiol. 78:285–291. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jang JS, Jin HY, Seo JS, et al: A
meta-analysis of randomized controlled trials appraising the
efficacy and safety of cilostazol after coronary artery stent
implantation. Cardiology. 122:133–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakamura T, Tsuruta S and Uchiyama S:
Cilostazol combined with aspirin prevents early neurological
deterioration in patients with acute ischemic stroke: a pilot
study. J Neurol Sci. 313:22–26. 2012. View Article : Google Scholar
|
|
11
|
Dangas G, Mehran R, Abizaid AS, et al:
Combination therapy with aspirin plus clopidogrel versus aspirin
plus ticlopidine for prevention of subacute thrombosis after
successful native coronary stenting. Am J Cardiol. 87:470–472.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rogers KC, Faircloth JM and Finks SW: Use
of cilostazol in percutaneous coronary interventions. Ann
Pharmacother. 46:839–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geng DF, Liu M, Jin DM, Wu W, Deng J and
Wang JF: Cilostazol-based triple antiplatelet therapy compared to
dual antiplatelet therapy in patients with coronary stent
implantation: a meta-analysis of 5,821 patients. Cardiology.
122:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sekiguchi M, Hoshizaki H, Adachi H,
Ohshima S, Taniguchi K and Kurabayashi M: Effects of antiplatelet
agents on subacute thrombosis and restenosis after successful
coronary stenting: a randomized comparison of ticlopidine and
cilostazol. Circ J. 68:610–614. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maher CG, Sherrington C, Herbert RD,
Moseley AM and Elkins M: Reliability of the PEDro scale for rating
quality of randomized controlled trials. Phys Ther. 83:713–721.
2003.PubMed/NCBI
|
|
16
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zintzaras E and Ioannidis JP:
Heterogeneity testing in meta-analysis of genome searches. Genet
Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peters JL, Sutton AJ, Jones DR, Abrams KR
and Rushton L: Comparison of two methods to detect publication bias
in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong B, Qian JY, Fan B, Jin XJ and Ge JB:
A randomized trial of cilostazol versus ticlopidine for
anti-platelet therapy after coronary artery stenting for prevention
of restenosis. Chin J Intervent Cardiol. 14:170–172. 2006.(In
Chinese).
|
|
20
|
Inoue T, Uchida T, Sakuma M, et al:
Cilostazol inhibits leukocyte integrin Mac-1, leading to a
potential reduction in restenosis after coronary stent
implantation. J Am Coll Cardiol. 44:1408–1414. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kamishirado H, Inoue T, Mizoguchi K, et
al: Randomized comparison of cilostazol versus ticlopidine
hydrochloride for antiplatelet therapy after coronary stent
implantation for prevention of late restenosis. Am Heart J.
144:303–308. 2002. View Article : Google Scholar
|
|
22
|
Kozuma K, Hara K, Yamasaki M, et al:
Effects of cilostazol on late lumen loss and repeat
revascularization after Palmaz-Schatz coronary stent implantation.
Am Heart J. 141:124–130. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park SW, Lee CW, Kim HS, et al: Effects of
cilostazol on angiographic restenosis after coronary stent
placement. Am J Cardiol. 86:499–503. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takeyasu N, Watanabe S, Noguchi Y,
Ishikawa K, Fumikura Y and Yamaguchi I: Randomized comparison of
cilostazol vs ticlopidine for antiplatelet therapy after coronary
stenting. Circ J. 69:780–785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoon Y, Shim WH, Lee DH, et al: Usefulness
of cilostazol versus ticlopidine in coronary artery stenting. Am J
Cardiol. 84:1375–1380. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jennings DL and Kalus JS: Addition of
cilostazol to aspirin and a thienopyridine for prevention of
restenosis after coronary artery stenting: a meta-analysis. J Clin
Pharmacol. 50:415–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rubboli A, Milandri M, Castelvetri C and
Cosmi B: Meta-analysis of trials comparing oral anticoagulation and
aspirin versus dual antiplatelet therapy after coronary stenting.
Clues for the management of patients with an indication for
long-term anticoagulation undergoing coronary stenting. Cardiology.
104:101–106. 2005. View Article : Google Scholar
|
|
28
|
Cosmi B, Rubboli A, Castelvetri C and
Milandri M: Ticlopidine versus oral anticoagulation for coronary
stenting. Cochrane Database Syst Rev. CD0021332001.PubMed/NCBI
|
|
29
|
Schleinitz MD, Olkin I and Heidenreich PA:
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent
thrombosis: a meta-analysis of randomized trials. Am Heart J.
148:990–997. 2004. View Article : Google Scholar : PubMed/NCBI
|
